➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKesson
Medtronic
Express Scripts
Baxter

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for PLX3397


Email this page to a colleague

« Back to Dashboard

What is the drug development status for PLX3397?

PLX3397 is an investigational drug.

There have been 24 clinical trials for PLX3397. The most recent clinical trial was a Phase 2 trial, which was initiated on September 3rd 2020.

The most common disease conditions in clinical trials are Giant Cell Tumors, Melanoma, and Giant Cell Tumor of Tendon Sheath. The leading clinical trial sponsors are Plexxikon, Daiichi Sankyo Co., Ltd., and National Cancer Institute (NCI).

There are fifty-two US patents protecting this investigational drug and three hundred and ninety-one international patents.

Recent Clinical Trials for PLX3397
TitleSponsorPhase
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.Phase 2
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTDaiichi Sankyo Co., Ltd.Phase 3
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibDaiichi Sankyo, Inc.Phase 4

See all PLX3397 clinical trials

Clinical Trial Summary for PLX3397

Top disease conditions for PLX3397
Top clinical trial sponsors for PLX3397

See all PLX3397 clinical trials

US Patents for PLX3397

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PLX3397   Get Started Free Synthesis of a compound that modulates kinases Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)   Get Started Free
PLX3397   Get Started Free Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use Signal Pharmaceuticals, LLC (San Diego, CA)   Get Started Free
PLX3397   Get Started Free Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)m- ethyl)-2,2-difluoroacetamide Celgene Corporation (Summit, NJ)   Get Started Free
PLX3397   Get Started Free Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation AB SCIENCE (Paris, FR)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PLX3397

Drugname Country Document Number Estimated Expiration Related US Patent
PLX3397 Australia AU2016258027 2035-05-06   Get Started Free
PLX3397 Brazil BR112017023490 2035-05-06   Get Started Free
PLX3397 Brazil BR112017023540 2035-05-06   Get Started Free
PLX3397 Canada CA2984899 2035-05-06   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Colorcon
Moodys
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.